DHX9 and cancer: Rituximab is one of the commercially available mAbs, which is site-specifically conjugated with the Rha hapten to generate rituximab–Rha conjugates, to recruit anti-Rha antibodies onto the cancer cell surface and further form an immune complex that leads to magnifying ADCC and CDC simultaneously [128].